These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 3106085)

  • 1. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
    Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
    Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
    Zhang X; Chaudhry A; Chintala SK
    Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of epidermal plasminogen activator inhibitor.
    Hibino T; Izaki S; Izaki M
    FEBS Lett; 1986 Nov; 208(2):273-7. PubMed ID: 3096778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly-D-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin).
    Leung KC; Byatt JA; Stephens RW
    Thromb Res; 1987 Jun; 46(6):767-77. PubMed ID: 3114909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
    Coleman PL; Patel PD; Cwikel BJ; Rafferty UM; Sznycer-Laszuk R; Gelehrter TD
    J Biol Chem; 1986 Mar; 261(9):4352-7. PubMed ID: 2936742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
    Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
    Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
    Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH
    Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
    Walker B; Elmore DT
    Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
    Andreasen PA; Christensen TH; Huang JY; Nielsen LS; Wilson EL; Danø K
    Mol Cell Endocrinol; 1986 May; 45(2-3):137-47. PubMed ID: 3011558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of proteases type plasminogen activator and their inhibitor in cornea.
    Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
    Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
    Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
    J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.
    Gurewich V; Pannell R
    Blood; 1987 Mar; 69(3):769-72. PubMed ID: 2949785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet release protein which inhibits plasminogen activators.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1985 Jul; 38(7):825-30. PubMed ID: 3926830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interaction of plasminogen activator of urokinase type with human serum].
    Vakulina OP; Popkova EV; Isachenkov VA
    Vopr Med Khim; 1988; 34(4):32-6. PubMed ID: 3143185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
    Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
    Ann Otol Rhinol Laryngol; 1985; 94(3):293-6. PubMed ID: 3925865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microplate immunocapture assay for plasminogen activators and their specific inhibitors.
    Stephens R; Leung KC; Pöllänen J; Salonen EM; Vaheri A
    J Immunol Methods; 1987 Dec; 105(2):245-51. PubMed ID: 3121752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.